FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / irs-economist-rebuttal-memo.docx
irs-economist-rebuttal-memo.docx · 1018-00009

Parties

KOVEL ARRANGEMENT WHITMORE VALUATION LLC
Penterra Pharmaceuticals Corp
Whitmore Valuation Group LLC
Harkness LLP
Engagement Whitmore Valuation Group LLC
Associates LLP
Structure Overview Penterra Pharmaceuticals Corp
Penterra Manufacturing Ireland Ltd

Dates

October 12, 2023
January 22, 2024
June 20, 2022
March 15, 2012
July 1, 2012

Amounts

$380,400,000
$380.4
$235.01
$188.04
$42.65
$278
$361
$312
$852
€47.2

Obligations

Where material differences exist between the controlled and uncontrolled transactions, adjustments must be made to account for those differences under Treasury Regulation § 1
482-4(c)(2)(ii), or the purported comparable must be rejected
482-4(c)(2)(ii) expressly requires that if there are material differences between the controlled and uncontrolled transactions, adjustments must be made to account for those differences
482-1(c) provides that the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result (the "best method rule")
The regulation is explicit that RABs must be determined on a prospective (ex ante) basis, using projections of benefits made at the beginning of each cost-sharing period
482-7(d), which specifies the categories of costs that must be included in the Coss pool for purposes of determining each participant's cost-sharing obligation